Battlegrounds of treatment resistance: decoding the tumor microenvironment
- 25 March 2025
- journal article
- review article
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- p. 1-19
Abstract
The tumor microenvironment (TME) emerges as a formidable actor in the cancer treatment landscape, wielding the power to thwart therapeutic efficacy across various modalities, including chemotherapy, radiotherapy, immunotherapy, targeted therapy, and hormonal therapy. This intricate ecosystem comprising diverse cellular constituents, signaling molecules, and the extracellular matrix fosters a dynamic interplay that profoundly influences tumor behavior and treatment outcomes. This review explores the mechanisms through which the TME drives resistance to standard therapies, emphasizing key factors such as hypoxia, immune evasion, and metabolic reprogramming. Furthermore, we illuminate innovative strategies aimed at reprogramming this hostile environment, including the application of therapeutic vaccines, CAR T cell therapy, and combination immunotherapies designed to enhance anti-tumor responses. By advocating for multidimensional approaches that dismantle the TME’s barriers to effective treatment, this review calls for a transformative shift in cancer treatment paradigms. By bridging the gap between the TME’s complexities and targeted therapeutic strategies, we pave the way for targeted interventions that promise to enhance clinical outcomes and improve patient prognosis in the relentless battle against cancer.Keywords
This publication has 218 references indexed in Scilit:
- Abiraterone or Enzalutamide for Patients With Metastatic Castration-Resistant Prostate CancerJAMA Network Open, 2024
- Engineered extracellular vesicles: A new approach for targeted therapy of tumors and overcoming drug resistanceCancer Communications, 2023
- Chitosan‐based nanoscale systems for doxorubicin delivery: Exploring biomedical application in cancer therapyBioengineering & Translational Medicine, 2022
- Tumor‐Microenvironment‐Responsive Nanomedicine for Enhanced Cancer ImmunotherapyAdvanced Science, 2021
- Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment OutcomesAdvanced Therapeutics, 2021
- Role of tumor microenvironment in the regulation of PD‐L1: A novel role in resistance to cancer immunotherapyJournal of Cellular Physiology, 2020
- Antibody–drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successesJournal of Cellular Physiology, 2018
- CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A reviewJournal of Cellular Physiology, 2018
- Tuning the Microenvironment: Click‐Crosslinked Hyaluronic Acid‐Based Hydrogels Provide a Platform for Studying Breast Cancer Cell InvasionAdvanced Functional Materials, 2015
- Antimetabolites in Cancer Therapy2008